Sardine-enriched Diet for Prevention Type 2 Diabetes

July 18, 2018 updated by: Diana Alicia Diaz Rizzolo, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Sardine-enriched Diet for Prevention Type 2 Diabetes in Elderly and Prediabetic Population

The hypothesis formulated is that 200 g of sardine on a weekly basis will have a favourable impact avoiding the natural development of the pathology due to changes in the biochemical profile, the anthropometrics, inflammatory markers, changes in gut microbiota populations, also in transcriptomics and metabolomics.

Study Overview

Study Type

Interventional

Enrollment (Actual)

182

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Barcelona, Spain, 08036
        • Diana A Diaz Rizzolo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

63 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • glycaemia between 100-125 md / dL or ≥5.7% HbA1c

Exclusion Criteria:

  • treatment with oral antidiabetic drugs
  • any nutritional education to prevent T2D
  • Suspect or known hypersensitivity to sardine or related fish
  • Chronic treatment with oral steroids and / or AINES
  • Treatment with oral antidiabetic agents and / or insulin
  • Treatment with immunosuppressive drugs
  • Diagnosis of active neoplasm
  • Diagnosis of HIV or AIDS
  • Abnormal liver profile (> 6 times normal values)
  • Diagnosis of Acute Psychiatric Sdr
  • Presence of serious acute concomitant disease, which it requires more than 7 days of recovery.
  • Major cardiovascular event (stroke, myocardial infarction) in the month prior to randomization.
  • Any other condition that the investigator considers to be inoperative so that the subject conducts the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
They received a common T2D-preventive diet
Experimental: Sardine group
They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
type 2 diabetes new onset
Time Frame: Change from Baseline at 12 months
incidence of new diagnosis of type 2 diabetes
Change from Baseline at 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
adiponectin
Time Frame: Change from Baseline at 12 months
adiponectin levels
Change from Baseline at 12 months
quantification of gut microbiota populations
Time Frame: Change from Baseline at 12 months
quantification by q-PCR
Change from Baseline at 12 months
gene expression
Time Frame: Change from Baseline at 12 months
relative expression related genes by RT q-PCR (Real Time Quantitative Reverse transcription polymerase chain reaction)
Change from Baseline at 12 months
metabolomics study of dietary biomarkers and health biomarkers [(1) Fatty acyls, bile acids, steroids and lysoglycerophospholipids, (2) Glycerolipids, glycerophospholipids, sterol lipids and sphingolipids, (3) Amino acids.]
Time Frame: Change from Baseline at 12 months
endogenous metabolic profiles of serum samples will be studied using ultra-high performance liquid chromatography - mass spectrometry (UHPLC-MS). The same unit for measurements [log2 (fold change)]
Change from Baseline at 12 months
glucose homeostasis
Time Frame: Change from Baseline at 12 months
glucose (mg/dl)
Change from Baseline at 12 months
insulin levels
Time Frame: Change from Baseline at 12 months
insulin (mU/L)
Change from Baseline at 12 months
HOMA-IR (homeostasis model assessment insulin resistance)
Time Frame: Change from Baseline at 12 months
insulin resistance index
Change from Baseline at 12 months
HOMA-B (homeostasis model assessment B cell function)
Time Frame: Change from Baseline at 12 months
B cella function
Change from Baseline at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2014

Primary Completion (Actual)

July 1, 2017

Study Completion (Actual)

July 1, 2017

Study Registration Dates

First Submitted

March 21, 2018

First Submitted That Met QC Criteria

June 4, 2018

First Posted (Actual)

June 15, 2018

Study Record Updates

Last Update Posted (Actual)

July 19, 2018

Last Update Submitted That Met QC Criteria

July 18, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Sardine

3
Subscribe